

Session Title: #71: Melanoma Immunotherapy: Current Status, Future Opportunities

Session Type: Education Session

Date: Saturday, June 5

Location: S406 (Vista Room)

Time: 8:00 AM - 9:15 AM

- Adoptive T Cell transfer

Patrick Hwu, MD

- Checkpoint blockade

Jedd D. Wolchok, MD, PhD

- Melanoma vaccines

Craig L. Slingluff, MD

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #136: Ocular Melanoma

Session Type: Clinical Problems in Oncology Session

Date: Saturday, June 5

Location: E451a

Time: 9:45 AM - 11:00 AM

- Background and treatment of primary ocular melanoma

J. William Harbour, MD

- Regional therapy for ocular melanoma
James F. Pingpank, MD, FACS
 - Systemic therapy for metastatic ocular melanoma
Takami Sato, MD, PhD
-

Session Title: #120: Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention

Session Type: Meet the Professor Session

Date: Saturday, June 5

Location: E451b

Time: 1:00 PM - 2:15 PM

- Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention
Aleksandar Sekulic, MD, PhD
-

Session Title: #162: Melanoma/Skin Cancers

Session Type: Oral Abstract Session

Date: Saturday, June 5

Location: S406 (Vista Room)

Time: 1:00 PM - 4:00 PM

- Melanoma/Skin Cancers
Thomas Gajewski, MD, PhD
- Melanoma/Skin Cancers
Tim Eisen, PhD, FRCP
- #8504-E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma.
David H. Lawson
- #8505-Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961.
Alexander M. Eggermont, MD, PhD
- #LBA8506-Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial.
Jean Jacques Grob

- Discussion

Michael S. Sabel, MD, FACS

- #8507-Interleukin-21 (IL-21) has activity in patients (pts) with metastatic melanoma (MM).

Teresa M. Petrella

- #8508-First report of a randomized phase II trial of multi-epitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells in patients with metastatic melanoma: An Eastern Cooperative Oncology Group study (E1602).

Craig L. Slingluff, MD

- #8509-Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma.

F. Stephen Hodi, MD

- Discussion

Antoni Ribas, MD

- #8510-Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: Final results of a phase II multicenter study.

Eve Maubec

- #8511-Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma.

Keith T. Flaherty, MD

- #LBA8512-A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma.

James F. Pingpank, MD, FACS

- Discussion

Dirk Schadendorf, MD

Session Title: #230: Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets

Session Type: Clinical Science Symposium

Date: Saturday, June 5

Location: S406 (Vista Room)

Time: 4:30 PM - 6:00 PM

- Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets

Kevin B. Kim, MD

- Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets

David B. Solit, MD

- #8500-Clinical outcome and pathologic features associated with NRAS mutation in cutaneous melanoma.

Bianca Alix Devitt

- #8501-Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.

Sapna Pradyuman Patel, MD

- Discussion

Neal Rosen, MD, PhD

- #8502-Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group trial S0438.

Kim Allyson Margolin, MD

- #8503-Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Richard Kefford

- Discussion

Grant A. McArthur, PhD

Session Title: #37: Cutaneous Cancer Syndromes

Session Type: Education Session

Date: Saturday, June 5

Location: E353

Time: 4:45 PM - 6:00 PM

- Overview of cutaneous cancer syndromes

Sancy Ann Leachman, MD

- Melanoma genetics and risk assessment

Hensin Tsao, MD

- Advances in Cowden's Syndrome

Stephen B. Gruber, MD, PhD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodi, MD

Session Title: #209: Melanoma/Skin Cancers

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

48A #8533-Phase I/II study of the combination of decitabine (DAC) and temozolomide (TMZ) in patients (pts) with metastatic melanoma (MM).

Hussein Abdul-Hassan Tawbi

48B #8534-Chemoablation of metastatic melanoma with rose bengal (PV-10).

Sanjiv S. Agarwala

48C #8535-A phase I trial of intra-lymph-node administration of a novel immunotherapeutic regimen (MKC1106-MT) in patients with advanced melanoma.

Jeffrey S. Weber

48D #8536-Dacarbazine (DTIC) plus bevacizumab (B) combination therapy in

48E #8537-Plitidepsin (APL) alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM).

Elizabeth R. Plummer

48F #8538-Evaluation of FOXP3 microsatellite polymorphisms in high-risk melanoma patients receiving adjuvant interferon.

Helen Gogas

48G #8539-Screening tools for interferon-related cognitive decline in melanoma patients.

Daniel Combs

48H #8540-The impact of multiple primary cutaneous melanomas on survival of 2,942 patients with metastatic melanoma.

Rajmohan Murali

49A #8541-A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma.

John Munn Kirkwood

49B #8542-Prognostic factors for survival after first recurrence of melanoma.

Ting Tu

49C #8543-Correlation of polymorphic variants into the susceptibility of CDKN2 locus with melanoma outcome.

Giuseppe Palmieri

49D #8544-Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma.

Peter A Prieto, MD, MPH

49E #8545-Sunitinib therapy for metastatic melanomas with KIT aberrations.

David R. Minor

49F #8546-Preclinical analyses of a new gamma-secretase inhibitor targeting notch signaling in melanoma.

Laura Poliseno

49G #8547-Clinical outcome following therapeutic vaccination with autologous mRNA electroporated dendritic cell (DC) vaccines in patients with advanced melanoma.

Sofie Wilgenhof

49H #8548-Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma.

Georgina Long, MBBS, PhD, FRACP

50A #8549-A predictive model to determine the likelihood of positive sentinel lymph node biopsy in thin melanomas.

Suraj S. Venna

50B #8550-Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update.

Vojislav M. Vukovic

50C #8551-Correlation of stem cell marker nestin expression on circulating melanoma cells with extension of disease and survival.

Alberto Fusi, MD

50D #8552-Phase I/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma: Looking for predictive markers of efficacy.

Caroline Robert

50E #8553-The use of integrative genomics to define molecular signatures of melanoma histologic subtypes.

Amy Elizabeth Rose

50F #8554-Preclinical analysis of targeting miR-182 against melanoma liver metastasis.

Chanh Trung Huynh

50G #8555-Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naïve stage IV melanoma patients.

Benjamin Weide

50H #8556-Patterns of recurrence in 208 patients with Merkel cell carcinoma.

Tawnya Lynn Bowles

51A #8557-Relation between baseline LDH and tumor burden in advanced melanoma in two phase III trials of oblimersen-dacarbazine (OBL-DTIC) versus DTIC.

Celeste Lebbé

51B #8558-MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab (SAKK 50/07).

Adrian F. Ochsenein

51C #8559-Induction of apoptosis in human melanoma by the BRAF inhibitor PLX4720: The key to therapeutic success?

Peter Hersey

51D #8560-Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma.

Jose Lutzky, MD, FACP

51E #8561-Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma.

Patrick Alexander Ott

51F #8562-Phase II study of the src family kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.

Thomas Gajewski, MD, PhD

51G #8563-The impact of physician specialty on quality of melanoma care.

Janice N. Cormier

51H #8564-Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma.

Lu Si

52A #8565-CD20-immunotargeting of malignant melanoma.

Stephan N. Wagner

52B #8566-Enhancing DNA repair in the skin: A pilot study of low-dose chloroquine and ultraviolet light.

Holly E Kanavy

52C #8567-Changes in regional immunity and metastasis in melanoma.

Aaron Scott Mansfield

52D #8568-Effect of TLR4 engagement on TLR3-induced proinflammatory signaling in dendritic cells through IL-10, STAT3, and p38-dependent pathways and on antimelanoma CD8+ T-cell priming.

Dusan Bogunovic

52E #8569-Interleukin-2-induced fever in relation to objective tumor response and survival in patients with metastatic melanoma.

Mai-Britt Bjørklund Ellegaard, MA

52F #8570-Identification of tyrosinase polymorphisms for use in melanoma risk assessment.

Eleftheria Pervolaraki

52G #8571-Hair depigmentation as an indicator of durable response to CTLA-4 therapy.

Anna C. Pavlick, MD

52H #8572-N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM).

Roxana Stefania Dronca

53A #8573-Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone.

Agop Y. Bedikian

53B #8574-Effect of a novel cross-talk mechanism on the RAF/MEK/ERK and PI3K/AKT/mTOR pathways in melanoma: Role of ERK-mediated suppression of PTEN expression.

Ludovica Ciuffreda

53F #8575-In vivo metabolic activity and transcriptional profiling in melanoma (MM) patients during sorafenib and dacarbazine (DTIC) treatment.

Marjam Jeanette Barysch

53G #8576-Role of lymph-node ultrasonography (US) in the follow-up of melanoma patients to detect nodal recurrence after sentinel lymph node biopsy (SNLB): A prospective cohort study.

Philippe Saiag

53H #8577-Final results of a pilot study using sunitinib malate in patients with stage IV uveal melanoma.

Lukman Adeoju Tijani

54A #8578-Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E.

Svetomir Markovic

54B #8579-Management of cutaneous metastases by electrochemotherapy.

Julie Gehl

54F #8580-Immunomodulatory gene expression at the fetomaternal interface and in melanoma: Tolerance meets inflammation.

Shernan G. Holtan

54G #8581-Diagnostic imaging modalities for the surveillance of melanoma patients: A meta-analysis.

Yan Xing

54H #8582-Relationship between dose, exposure, and antitumoral activity of sorafenib in melanoma.

Nicolas Pécuchet

55A #8583-Patterns of disease spread in metastatic mucosal melanoma.

Kevin N O'Regan

55B #8584-Targeting SRC kinase (SRC) in melanoma cells.

Alex J. Eustace

55C #8585-Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07).

Gregor Fuerstenberger

55D #8586-A phase II clinical trial of a novel combinatorial antitumor immunotherapy for patients with high-risk resected stage III and metastatic melanoma.

Adam Irwin Riker

55E #8587-Prognostic value of serum YKL-40 in stage I&B-III melanoma patients receiving adjuvant interferon therapy.

Merete Krogh

55F #8588-Interleukin-10 as a prognostic factor in patients treated with autologous melanoma cell vaccine.

Amit Mahipal

55G #8589-Electrochemotherapy with bleomycin: A local treatment with possible systemic implication.

Alessandro Testori

55H #8590-Dual mechanistic function of MDSC subsets in melanoma resistance.

Ernest C. Borden, MD

56A #8591-Immunohistochemical expression of Dicer in melanoma.

Carlo Capalbo

56B #8592-PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial.

Mario E. Lacouture, MD

56D #8594-Utility of 3-year torso CT and head imaging in asymptomatic patients with high-risk melanoma.

Erin Rachelle DeRose

56E #8595-Comparison of classification systems in melanoma sentinel nodes: An analysis of 697 patients from a single center.

Ralf Gutzmer

56F #8596-Prognostic relevance of increased detection of lymphovascular invasion in primary melanoma using D2-40 and CD34 compared to routine histology.

Farbod Darvishian

56G #8597-Effect of mutational status on response, PFS, or OS after treatment with IL-2 for metastatic melanoma.

Richard Wayne Joseph

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture
Douglas W. Blayney, MD
- Plenary Session including Science of Oncology Award and Lecture
Daniel F. Hayes, MD
- Plenary Session including Science of Oncology Award and Lecture
Frank McCormick, PhD, FRS
- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger
- Discussion
Elizabeth A. Eisenhauer, MD
- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).
Elisabeth A. Quoix
- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).
Yung-Jue Bang
- Discussion
Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #82: Nonmelanoma Skin Cancers: New Insights, New Directions

Session Type: Education Session

Date: Sunday, June 6

Location: S406 (Vista Room)

Time: 4:45 PM - 6:00 PM

- Non-melanoma skin cancer in the immunosuppressed patient

Juergen C Becker, MD, PhD

- Merkel cell carcinoma: new biologic insights and management strategies

Paul Nghiem, MD, PhD

- Molecular pathways in basal cell carcinoma and clinical trials

Jean Y Tang, MD, PhD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer
Claire F. Verschraegen, MD
 - Discussion: Myeloma
Jean L. Harousseau, MD
 - Discussion: Cancer Prevention/Epidemiology
Scott Michael Lippman, MD
-

Session Title: #188: Melanoma/Skin Cancers

Session Type: Poster Discussion Session

Date: Monday, June 7

Location: S403

Time: 8:00 AM - 12:00 PM

- Melanoma/Skin Cancers
Ravi K. Amaravadi, MD
- Melanoma/Skin Cancers
Gregory A. Daniels, MD, PhD

1 #8513-Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008.

Jeffrey Alan Sosman, MD

2 #8514-Early ultrasound criteria drive sensitivity for detection of sentinel node metastases in melanoma patients: A prospective study in 800 patients.

Christiane A. Voit

3 #8515-Report card for compliance with NCCN guidelines in the surgical management of cutaneous melanoma across the United States: Time for remedial classes?

Nabil Wasif

4 #8516-Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study.

Michael B. Atkins, MD

5 #8517-Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008.

Vernon K Sondak, MD

- Discussion

Julie R. Lange, MD

6 #8518-Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers.

Lore Decoster, MD

7 #8519^--A phase II randomized study of ramucirumab (IMC□1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM).

Richard D. Carvajal

8 #8520-Phase II trial of bevacizumab and high-dose interferon alpha-2b in metastatic melanoma.

Valerie P Grignol, MD

9 #8521-First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).

Reinhard Dummer

10 #8522-Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma.

Roger Mouawad

- Discussion

David F. McDermott, MD

11 #8523-Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

Donald P. Lawrence

12 #8524-Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.

Ahmad A. Tarhini

13 #8525-Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.

Omid Hamid

14 #8526-Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.

Axel Hauschild

- Discussion

Henry B. Koon, MD

15 #8527-A phase II study of imatinib for advanced melanoma patients with KIT aberrations.

Jun Guo, MD, PhD

16 #8528-Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM).

Lynn G. Feun

17 #8529-Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma.

Grant A. McArthur, PhD

18 #8530-Phase II study of vorinostat in patients with advanced melanoma.

Naomi B. Haas

19 #8531-Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma.

Wen-Jen Hwu

20 #8532-A phase I/II trial of DTIC and dasatinib in metastatic melanoma.

Alain Patrick Algazi

- Discussion

Anna C. Pavlick, MD

Session Title: #255: Melanoma/Skin Cancers

Session Type: Poster Discussion Session

Date: Monday, June 7

Location: S406 (Vista Room)

Time: 11:00 AM - 12:00 PM

- Melanoma/Skin Cancers

Gregory A. Daniels, MD, PhD

- Melanoma/Skin Cancers

Ravi K. Amaravadi, MD

1 #8513-Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008.

Jeffrey Alan Sosman, MD

2 #8514-Early ultrasound criteria drive sensitivity for detection of sentinel node metastases in melanoma patients: A prospective study in 800 patients.

Christiane A. Voit

3 #8515-Report card for compliance with NCCN guidelines in the surgical management of cutaneous melanoma across the United States: Time for remedial classes?

Nabil Wasif

4 #8516-Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study.

Michael B. Atkins, MD

5 #8517-Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008.

Vernon K Sondak, MD

- Discussion

Julie R. Lange, MD

6 #8518-Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers.

Lore Decoster, MD

7 #8519^--A phase II randomized study of ramucirumab (IMC□1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM).

Richard D. Carvajal

8 #8520-Phase II trial of bevacizumab and high-dose interferon alpha-2b in metastatic melanoma.

Valerie P Grignol, MD

9 #8521-First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).

Reinhard Dummer

10 #8522-Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma.

Roger Mouawad

- Discussion

David F. McDermott, MD

11 #8523-Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

Donald P. Lawrence

12 #8524-Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.

Ahmad A. Tarhini

13 #8525-Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.

Omid Hamid

14 #8526-Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.

Axel Hauschild

- Discussion

Henry B. Koon, MD

15 #8527-A phase II study of imatinib for advanced melanoma patients with KIT aberrations.

Jun Guo, MD, PhD

16 #8528-Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM).

Lynn G. Feun

17 #8529-Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma.

Grant A. McArthur, PhD

18 #8530-Phase II study of vorinostat in patients with advanced melanoma.

Naomi B. Haas

19 #8531-Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma.

Wen-Jen Hwu

20 #8532-A phase I/II trial of DTIC and dasatinib in metastatic melanoma.

Alain Patrick Algazi

- Discussion

Anna C. Pavlick, MD

Session Title: #133: Management of Less Common Head and Neck Cancers

Session Type: Clinical Problems in Oncology Session

Date: Monday, June 7

Location: E451a

Time: 11:30 AM - 12:45 PM

- Salivary gland cancer

David J. Adelstein, MD

- Nasopharyngeal carcinoma
Quynh-thu Le, MD
 - Cutaneous melanoma of the head and neck
Carol Rossier Bradford, MD
-

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III
Kathy Miller, MD
- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy
Kathy Miller, MD
- Discussion: Lung Cancer - Metastatic
Charles M. Rudin, MD, PhD
- Discussion: Sarcoma
Gary K. Schwartz, MD
- Discussion: Gastrointestinal (Noncolorectal) Cancer
C. D. Blanke, MD
- Discussion: Head and Neck Cancer
Everett E. Vokes, MD